Company Overview and News

2
Tokyo stocks rise further on easing U.S.-China trade concerns

19h japantimes.co.jp
Stocks continued to rise on the Tokyo Stock Exchange on Wednesday as investors were relieved that the economic impact of the latest development of U.S.-China trade friction is likely to be limited.
ADTTF TM SMFG TYT SFTBF TOYOF SMFNF TOELY SUOPY 8316 8306 7203 MUFG 9984 SUMCF 8750 TOELF 8035 MBFJF ATEYY MTU SFTBY

 
Nikkei drops, led by chip stocks, machine tool makers; Kubota falls

2018-09-12 reuters
TOKYO, Sept 12 (Reuters) - Japan’s Nikkei fell on Wednesday as chip-related stocks tracked weakness in their U.S. counterparts overnight and as machine tool makers weakened after downbeat industry data.
MRSKY SUOPY ADTTF KUBTY SUMCF ATEYY TSGMY

 
Nikkei drops as chip-related stocks, machine tool makers weaken

2018-09-12 thehindubusinessline
The Nikkei share average was down 0.4 per cent at 22,571.76 points by the midday break, after rising 1.3 per cent to a one-week high on Tuesday.
MRSKY SUOPY ADTTF SUMCF ATEYY TSGMY

 
Nikkei drops as chip stocks, tool makers sold, Pioneer volatile

2018-09-12 reuters
TOKYO, Sept 12 (Reuters) - Japan’s Nikkei fell on Wednesday as chip-related stocks tracked weakness in their U.S. counterparts overnight and as machine tool makers weakened after downbeat industry data.
MRSKY SUOPY ADTTF SUMCF ATEYY TSGMY

 
Japan stocks rise on weaker yen, Nasdaq gain; US deal lifts Renesas

2018-09-11 reuters
TOKYO, Sept 11 (Reuters) - Japanese stocks had their best day in four weeks on Tuesday, with exporters lifted by the yen’s weakening against the dollar and technology shares boosted by gains for Wall Street counterparts.
ADTTF BRDCF TM RNECF TYT TOYOF TOELY KYO SUOPY 6723 7203 IDTI RNECY SUMCF 8035 TOELF ATEYY

 
Nikkei rises as yen, Nasdaq boost exporters, tech shares

2018-09-11 thehindubusinessline
Japanese stocks rose on Tuesday, with exporters lifted by the yen's weakening against the dollar and technology shares taking heart from gains in their American peers. The Nikkei share average was 0.91 per cent higher at 22,575.43.
ADTTF BRDCF TM RNECF TYT TOYOF TOELY KYO SUOPY 6723 7203 IDTI RNECY SUMCF 8035 TOELF ATEYY

 
Japan stocks gain as yen, Nasdaq boost exporters and tech shares

2018-09-11 reuters
TOKYO, Sept 11 (Reuters) - Japanese stocks rose on Tuesday, with exporters lifted by the yen’s weakening against the dollar and technology shares taking heart from gains in their American peers.
ADTTF BRDCF TM RNECF TYT TOYOF TOELY KYO SUOPY 6723 7203 IDTI RNECY SUMCF 8035 TOELF ATEYY

 
Nikkei continues slide into 6th session on trade worries; chip equipment makers dive

2018-09-07 reuters
TOKYO, Sept 7 (Reuters) - The Nikkei extended its decline to a sixth straight session on Friday, dropping to a 2-1/2-week low as investors sold chip equipment makers and fretted over reports that U.S. President Donald Trump could be contemplating taking on Japan over trade.
PCRFY KYO SUOPY ADTTF SUMCF 8035 TOELF ATEYY TOELY

 
Nikkei drops to 1-1/2-week low on trade worries

2018-09-07 thehindubusinessline
The benchmark share average dropped 0.9 per cent to 22,278.04 points by mid-morning, after falling to as low as 22,210.67, its lowest level since August 22. - Reuters
7261 PCRFY ADTTF MZDAY TM TYT TOYOF TOELY KYO SUOPY MZDAF 7203 SUMCF 8035 TOELF ATEYY

 
Nikkei drops to 1-1/2-week low on trade worries; chip equipment makers dive

2018-09-07 reuters
TOKYO, Sept 7 (Reuters) - The Nikkei dropped to 1-1/2-week lows on Friday as investors sold chip equipment makers and fretted over reports that U.S. President Donald Trump could be contemplating taking on Japan over trade.
7261 PCRFY ADTTF MZDAY TM TYT TOYOF TOELY KYO SUOPY MZDAF 7203 SUMCF 8035 TOELF ATEYY

 
Japan's Nikkei on 7-day winning run, supported by tech shares

2018-08-29 reuters
TOKYO, Aug 29 (Reuters) - Japan’s Nikkei share average rose for the seventh straight session on Wednesday as technology shares advanced along with their Wall Street counterparts.
7261 ADTTF MZDAY TM TYT TOYOF TOELY KDDIY SUOPY CHUEF MZDAF 7203 SUMCF KDDIF 8035 TOELF ATEYY 8892

 
Nikkei heads for 7th straight session of gains

2018-08-29 thehindubusinessline
The Nikkei was up 0.27 per cent at 22,875.12, headed for its seventh straight session of gains. - Reuters
7261 ADTTF MZDAY TM TYT TOYOF TOELY SUOPY CHUEF MZDAF 7203 SUMCF 8035 TOELF ATEYY 8892

 
Japanese stocks edge up, tech shares track rise in Wall Street peers

2018-08-29 reuters
TOKYO, Aug 29 (Reuters) - Japanese shares edged higher on Wednesday, tracking gains on Wall Street, although profit-taking and lingering trade concerns limited the market’s gains.
7261 ADTTF MZDAY TM TYT TOYOF TOELY SUOPY CHUEF MZDAF 7203 SUMCF 8035 TOELF ATEYY 8892

 
Tokyo stocks higher on buybacks

2018-08-22 japantimes.co.jp
Stocks went up on the Tokyo Stock Exchange on Wednesday, buoyed by repurchases after recent drops.
7261 MZDAY TM SUGBY TYT TOYOF TOELY TOZOF SUOPY MZDAF 7203 7269 8358 SUMCF 8035 TOELF

1
Tokyo stocks turn lower in thin trading

2018-08-20 japantimes.co.jp
Stocks fell back on the Tokyo Stock Exchange on Monday, as investors retreated to the sidelines amid a dearth of fresh trading incentives.
ITOCY JAPAF 2914 SFTBF JFEEF TOELY KDDIY SUOPY JAPAY ITOCF 5411 9984 SUMCF KDDIF 8035 TOELF SFTBY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...